Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Long-Term Debt Repayments (2018)

Aclaris Therapeutics has reported Long-Term Debt Repayments over the past 1 years, most recently at $149000.0 for Q4 2018.

  • Quarterly results put Long-Term Debt Repayments at $149000.0 for Q4 2018, changed N/A from a year ago — trailing twelve months through Dec 2021 was $612000.0 (changed N/A YoY), and the annual figure for FY2021 was -$11.5 million, changed.
  • Long-Term Debt Repayments for Q4 2018 was $149000.0 at Aclaris Therapeutics, down from $164000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for ACRS hit a ceiling of $299000.0 in Q2 2018 and a floor of $36000.0 in Q1 2018.